Navigation Links
Cephalon Announces Strong Third Quarter Financial Results
Date:11/8/2007

Company Also Announces Agreement in Principle with U.S. Attorney's Office;

Earnings Exceed Company Guidance; Company Again Increases 2007 Earnings Guidance and Introduces 2008 Guidance

FRAZER, Pa., Nov. 8 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported third quarter 2007 sales of $428.7 million, compared to adjusted sales of $457.2 million for the third quarter of 2006 and within the company's previously issued guidance. Basic loss per common share for the third quarter of 2007 was $4.58. Excluding the settlement reserve increase, amortization expense and certain other items, basic adjusted income per common share during the quarter was $1.08, which compares to $1.71 for the third quarter of 2006 and exceeds the high end of the company's guidance range of $0.85 to $0.95.

During the third quarter, central nervous system (CNS) franchise sales increased 9 percent to $230.9 million and the pain franchise reported strong sales of $121.8 million, a decrease of only 33 percent despite generic competition to ACTIQ(R). Sales of other products were $76.0 million, an increase of 20 percent over the same period last year.

The company also announced that it has reached an agreement in principle with the U.S. Attorney's Office in Philadelphia and the U.S. Department of Justice with respect to the previously disclosed investigation of the company's sales and marketing practices. The company expects to pay $425 million as part of a comprehensive settlement of Federal and related state Medicaid claims. The company has increased its existing financial reserves for this matter accordingly. In addition, the company will agree to a single misdemeanor violation of the U.S. Food, Drug, and Cosmetic Act and will enter into a corporate integrity agreement with the Office of Inspector General of the U.S. Department of Health and Human Services. The terms of the settlement are subject to the final negotiation and execution o
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...wire-FirstCall/ -- ExonHit Therapeutics S.A.,(Alt...mpany, is pleased to,announce today that it has b...ndustrial Property) during the last edition of its..., "Since its inception, ExonHit consistently...e of its intellectual property and in particular f...
(Date:12/3/2008)...dangers of first- and secondhand smoke, an estimat...mokers. Exposure of a developing baby to harmful ...s an estimated 420,000 newborns each year and pose...e first study of its kind, a team of researchers h...lical cord blood to better understand the fetal he...
(Date:12/3/2008)...ne Product Agreement Executed to Support ConjuChem...and BAGSVAERD, Denmark, Dec. 3 /PRNewswire-FirstCa... Novozymes Biopharma UK Ltd., a subsidiary of Novo...nies have entered into a long-term Manufacturing a...ill exclusively supply its recombinant human album...
(Date:12/3/2008)...wire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL )...eading producer of single-wall,carbon nanotubes, ... under,which Sigma-Aldrich will distribute SWeNT,...d development community. , Under the terms ...distribute research quantities of SWeNT(R) CG 100,...
Breaking Biology Technology:ExonHit is Honoured by the "Innovation Trophy" From The National Institute of Industrial Property (INPI) 2ExonHit is Honoured by the "Innovation Trophy" From The National Institute of Industrial Property (INPI) 3Cutting the cord to determine babies' health risk from toxic exposure 2Cutting the cord to determine babies' health risk from toxic exposure 3Cutting the cord to determine babies' health risk from toxic exposure 4ConjuChem and Novozymes Enter Long-Term Supply Agreement for Recombumin(R) use in PC-DAC(TM):Exendin-4 2ConjuChem and Novozymes Enter Long-Term Supply Agreement for Recombumin(R) use in PC-DAC(TM):Exendin-4 3Sigma-Aldrich Signs Agreement With SouthWest NanoTechnologies to Distribute SWeNT(R) Single-Wall Carbon Nanotubes 2Sigma-Aldrich Signs Agreement With SouthWest NanoTechnologies to Distribute SWeNT(R) Single-Wall Carbon Nanotubes 3
..., , , , , , Multiporator / ..., , , , Transfo...15.540 07/2002 , , , , ,... , Microorganism , Pedioco... type , Bacteria, gram positive, ...
..., , , , , , Multiporator / ..., , , , Transfo...15.526 01/2002 , , , , ,... , Microorganism , Nocardi...ll type , Bacteria, gram positive, ...
..., , , , , , Multiporator / ..., , , , Transfo...15.525 01/2002 , , , , ,... , Microorganism , Nocardi...ell type , Bacteria, gram positive, ...
..., , , , , , Multiporator / ..., , , , Transfo...15.519 12/2001 , , , , ,... , Microorganism , Lactoco... Cell type , Bacteria, gram positiv...
Other Biology Technology:Pediococcus spp. 2Nocardia corallina 2Nocardia asteroides 2Lactococcus lactis 2
(Date:12/4/2008)... Wake Forest University,s School of Biomedical Eng...ics has received the Army Modeling and Simulation ...f of Staff of the Army and Director of the Army pr...ly help save eyesight and reduce morbidity and mor...ter was selected from 57 applicants from around th...
(Date:12/4/2008)...ant,s defences and causes disease,by sneakily di...,revealed in new research out today (4 December) ...on a pathogen which causes bacterial speck disease... black lesions on leaves,and fruit. Severe infect...to crops, and researchers believe that understandi...
(Date:12/4/2008)... with higher levels of omega-3 fatty acids in plas...of the European study IMMIDIET that will be publis...of Clinical Nutriti on, an official publication of... available on line ( www.ajcn.org ). The study su...drinks. This effect could be ascribed to compounds...
(Date:12/4/2008)...o monitor deforestation and degradation in tropica... and Betty Moore Foundation has awarded the Carneg... a $1.6-million grant to expand and improve CLASLi...new, user-friendly method that enables even the sm...ons (NGOs) to map tropical forests from their desk...
Breaking Biology News(10 mins):New dummy design and development wins US Department of Defense award 2Red alert! How disease disables tomato plant's 'intruder alarm' 2A little wine boosts omega-3 in the body: Researchers find a novel mechanism for a healthier heart 2A little wine boosts omega-3 in the body: Researchers find a novel mechanism for a healthier heart 3Tropical forest carbon monitoring gets big boost 2Senator Dean Barkley Pledges Action on HIV AIDS Epidemic 28008 1Senator Dean Barkley Pledges Action on HIV AIDS Epidemic 28008 2Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study 28006 1Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study 28006 2Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study 28006 3Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study 28006 4Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study 28006 5Animal Health International Inc Announces Its First Quarter Fiscal Year 2009 Earnings Release Date and Conference Call Information 28004 1Elaborate Network Drives When and Where Proteins Are Made 28003 1Elaborate Network Drives When and Where Proteins Are Made 28003 2
...olecule and snake venom may provide researchers wi...ases and developing new drugs. , Purdue University...a dendrimer, with a glowing identification tag tha...om cells from a rattlesnake. The scientists want t...centration and function of proteins involved in di...
...ity of Wisconsin School of Medicine and Public Hea...try taking part in a novel clinical trial investig...rm of severe coronary artery disease. , The trial,...lling subjects in the Autologous Cellular Therapy .... The first patient underwent the procedure March ...
...1st issue of G&D, Drs. Yong Sun Lee and Anindy...s tumor suppressors in vitro. , "Overexpression o...important tumors like uterine fibroids,?explains D...roRNAs have an important role in suppressing the o...the causation and perhaps the cure of a disease th...
...mals, males advertise to potential mates with show... levels. However, a new study suggests that, in fi...rations to be more susceptible to pathogens. , In ... a new study by Judith Mank (Uppsala University, ...howy traits ?such as bright colors or long tails a...
Other Biology News:Scientists use nanoparticle to discover disease-causing proteins 2UW launches study testing adult stem cells for heart damage repair 2UW launches study testing adult stem cells for heart damage repair 3
Proteinase K Buffer 3.9 ml
RNase Buffer 25 ml
Mouse cAMP / Ca2+ Signaling PathwayFinder, PCR Array for expression profiling from SuperArray Bioscience
Silencer siRNA Starter Kit from Ambion
Biology Products: